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Background: Genetic variation in immune response genes is associated with susceptibility and severity of
infectious diseases. Toll-like receptor (TLR) 9 polymorphisms are associated with susceptibility to develop
meningococcal meningitis (MM). The aim of this study is to compare genotype distributions of two TLR9
polymorphisms between clinical severity variables in MM survivors.
Methods: We used DNA samples of a cohort of 390 children who survived MM. Next, we determined the genotype
frequencies of TLR9 -1237 and TLR9 +2848 polymorphisms and compared these between thirteen clinical variables
associated with prognostic factors predicting adverse outcome of bacterial meningitis in children.
Results: The TLR9 -1237 TC and CC genotypes were associated with a decreased incidence of a positive blood
culture for Neisseria (N.) meningitidis (p= 0.014, odds ratio (OR) 0.5. 95% confidence interval (CI) 0.3 – 0.9). The TLR9
+2848 AA mutant was associated with a decreased incidence of a positive blood culture for N. meningitidis
(p= 0.017, OR 0.6, 95% CI 0.3 – 0.9). Cerebrospinal fluid (CSF) leukocytes per μL were higher in patients carrying the
TLR9 -1237 TC or CC genotypes compared to carriers of the TT wild type (WT) (p= 0.024, medians: 2117,
interquartile range (IQR) 4987 versus 955, IQR 3938). CSF blood/glucose ratios were lower in TLR9 -1237 TC or CC
carriers than in carriers of the TT WT (p= 0.017, medians: 0.20, IQR 0.4 versus 0.35, IQR 0.5). CSF leukocytes/μL were
higher in patients carrying the TLR9 +2848 AA mutant compared to carriers of GG or GA (p= 0.0067, medians: 1907,
IQR 5221 versus 891, IQR 3952).
Conclusions: We identified TLR9 genotypes associated with protection against meningococcemia and enhanced
local inflammatory responses inside the central nervous system, important steps in MM pathogenesis and defense.Background
The susceptibility, severity and prognosis of infectious
diseases depend on the ability of the host immune sys-
tem to respond to pathogens. Genetic variation of im-
mune response genes is associated with susceptibility to
and severity of infectious diseases [1]. Bacterial meningitis* Correspondence: samorretravel@yahoo.co.uk
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reproduction in any medium, provided the or(BM) is a serious and life-threatening infectious disease of
the central nervous system (CNS). Despite adequate anti-
biotic treatment and immunization strategies, mortality
remains high, especially in developing countries [2,3].
Neisseria (N.) meningitidis is a common causing patho-
gen of BM, both in the Western world as in developing
countries. The clinical course of meningococcal meningitis
(MM) is highly diverse and depends both on pathogen
characteristics as on the individual immune response of the
affected patient. Host-bacteria interactions are crucial in
defense against MM [4]. Acquisition of N. meningitidis may
lead to bacterial colonization in one patient and to fatal
MM or meningococcal septic shock in the other. Survivors
of BM have a high risk to develop neurological sequelae,
ranging from subtle learning and behavioral disorders to
deafness, paresis, and severe encephalopathy [5-7]. Innatel Ltd This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Distribution and characteristics of 13 severity variables in children with meningococcal meningitis
Severity variable Total
Continuous variable Median Range N
Duration of clinical illness before admission (days) 1.7 0.5 – 13.0 324
Rectal temperature (°C) 39.1 35.0 – 41.8 358
CSF leukocytes (/μL) 1 227 0.0 – 12 081 354
CSF/blood glucose ratio 0.34 0 – 1.77 280
CSF protein concentrations (g/L) 1.4 0.01 – 9.33 317
Blood leukocytes (x10^9 g/L) 16.2 0.8 – 57.2 382
C-reactive protein (CRP) (mg/L) 129 0 – 768 229
Dichotomous variable N N (%) N (%) N
N. meningitidis in blood culture No 187 (54) Yes 161 (46) 348
Convulsions No 355 (91) Yes 35 (9) 390
Level of consciousness at admission Normal 133 (35) Disturbed 242 (65) 375
ICU-admission No 302 (78) Yes 87 (22) 389
Main clinical diagnosis at discharge:(MM without/with sepsis) No sepsis 219 (56) Sepsis 171 (44) 390
Post meningitis hearing loss No 375 (96) Yes 15 (4) 390
Academic and behavioural limitations No 90 (61) Yes 57 (39) 147
Abbreviations: CSF: cerebrospinal fluid, ICU: intensive care unit, MM: meningococcal meningitis. Different numbers within groups are due to missing or non
determined data in patient records.
Sanders et al. BMC Infectious Diseases 2012, 12:112 Page 2 of 8
http://www.biomedcentral.com/1471-2334/12/112immunity is of particular importance as first line of defense
since it quickly senses pathogen invasion by pattern recog-
nition and subsequently initiates the immune response.
Toll-like receptors (TLRs) are a class of pathogen
recognition receptors (PRRs) that are key players of innate
immunity. It becomes increasingly clear that TLR mediated
meningeal inflammation is a pivotal factor for meningitis
associated tissue damage [8]. TLR9 is an intracellular
PRR which recognizes unmethylated Cytosine-phosphate-
Guanine (CpG) motives in pathogen DNA [9]. Menin-
gococcal CpG DNA enters TLR9 expressing cells by
endocytosis and then binds to TLR9. A cascade of intracel-
lular receptor signaling via myeloid differentiation protein
88 (MyD88) induces activation of transcription of nuclear
factor kappa B (NFkB) resulting in the production of cyto-
kines and chemokines [10]. TLR9 is present in phagocytos-
ing microglia and antigen presenting astrocytes inside the
CNS, cells responsible for adequate immune responses in
this compartment [11]. In a previous study we demon-
strated that the TLR9 +2848 SNP is associated with a
decreased susceptibility to MM [12]. Recent studies showed
that carriage of the TLR9 -1237 C variant allele creates a
potential nuclear factor kappa B (NFκB) binding site that
increases the transcriptional activity of TLR9 and enhances
cellular production of pro-inflammatory cytokines [13].
The purpose of this study is to compare the genotype
distributions of TLR9 -1237 and TLR9 +2848 single nu-
cleotide polymorphisms (SNPs) between thirteen clinical
severity variables in order to identify patients at risk for
severe disease and sequelae.Methods
The study population consists of 390 Dutch Caucasian chil-
dren who survived MM. These patients were identified by
the Dutch Reference Laboratory for Bacterial Meningitis.
The diagnosis of MM was based on a positive cerebrospinal
fluid (CSF) culture with N. meningitidis or meningococcal
antigens in the CSF. A total of 560 children were asked to
participate in the study and to return a sterile swab after
collecting their buccal DNA, of whom 390 patients (70%)
returned a buccal swab and informed consent form.
Patients were diagnosed between January 1990 and Decem-
ber 1995 and this cohort was previously described in detail
by Koomen et al. [6,7]. A similar validation cohort of 76
children developed BM between 1997 and 2001 [14]. Data
for our study were collected in the period from 2006 till
2010. Median age at infection was 2,5 (range 0.1 – 9.5)
years, 46.5% were female, 53.5% were male. Data on med-
ical history, physical examination, clinical course during
hospitalization, and laboratory results were gathered from
the medical records of all patients.
Children with ‘complex onset’ of meningitis (defined
as meningitis secondary to immune deficiency states,
cranial trauma, CNS surgery, and CSF shunt infections),
relapsing meningitis, or meningitis in the neonatal
period were excluded.
The Medical Ethical Committee of the VU University
Medical Center, Amsterdam, The Netherlands approved
this study.
TLR9 -1237 (rs5743836) and TLR9 +2848 (rs352140)
SNPs were analyzed in buccal DNA by TaqMan analysis
Figure 1 (A) Comparison of CSF leukocytes per μL in TLR9 -
1237 TC/CC carriers versus wild type (WT) carriers. Carriers of
TLR9 -1237 TC/CC had significantly higher CSF leukocyte numbers
compared to carriers of the TT WT (medians: 2117, interquartile
range (IQR) 4987 versus 955, IQR 3938). Mann–Whitney U test, *
p = 0.024. Abbreviatons: TLR: Toll-like receptor, SNP: single nucleotide
polymorphism, CSF: cerebrospinal fluid, ul: microliter. (B) Comparison
of CSF/blood glucose ratios in TLR9 -1237 TC/CC carriers versus WT
carriers. Carriers of TLR9 -1237 TC/CC genotypes display significant
lower ratios compared to carriers of the TT WT (medians: 0.20, IQR
0.4 versus 0.35, IQR 0.5). Mann–Whitney U test, * p= 0.017.
Abbreviatons: TLR: Toll-like receptor, SNP: single nucleotide
polymorphism, CSF: cerebrospinal fluid, ul: microliter. (C) Comparison
of CSF leukocytes per μL in TLR9 +2848 AA mutant carriers versus
GG/GA carriers. Carriers of the TLR9 AA mutant display significantly
higher CSF leukocyte levels compared to GG/GA carriers (medians:
1907, IQR 5221 versus 891, IQR 3952). Mann–Whitney U test, **
p= 0.0067. Abbreviatons: TLR: Toll-like receptor, SNP: single nucleotide
polymorphism, CSF: cerebrospinal fluid, ul: microliter.
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7000 Sequence Detection System (Applied Biosystems,
UK) was used to obtain data. Primers and probes we
used have been described previously [12]. The two TLR9
SNPs were chosen based on a study by Lazarus et al. In
three ethnic groups they found 20 TLR9 SNPs. A set of
four frequent TLR9 SNPs (TLR9 -1486, TLR9 -1237,
TLR9 +1174 and TLR9 +2848) accounted for more than
75% of all chromosomes in all three populations. Geno-
typing of both TLR9 -1237 T>C and TLR9 +2848 G>A
allows all four locus haplotypes to be distinguished [15].
We performed a literature search to identify severity
variables. We used clinical variables: duration of clinical
illness before admission, rectal temperature, convulsions,
level of consciousness at admission, ICU admission,
main clinical diagnosis at discharge (meningitis or men-
ingitis with sepsis), and post meningitis hearing loss.
Convulsions were defined as convulsions reported before
or at admission or during hospitalization. Post meningi-
tis hearing loss was defined as> 25 dB perceptive hear-
ing loss that was not present before meningitis occurred.
Laboratory variables at admission included: blood cul-
ture results, CSF leukocyte numbers, CSF/blood glucose
ratios, CSF protein concentrations, blood leukocyte
numbers, and C-reactive protein (CRP) concentrations
in serum. The selected variables were in accordance with
a recent systematic review summarizing the evidence
regarding prognostic factors predicting death or sequelae
after BM in children [16]. We distinguish continuous
and dichotomous variables. Continuous variables were
dichotomized according to clinical relevant cut off points
known from the literature i.e. duration of clinical illness
before admission> 2 days, rectal temperature≥ 38°C, CSF
leukocyte numbers> 600 and> 1000 [17,18], CSF blood/
glucose ratio≤ 0.4, CSF protein concentration> 0.7 g/L,
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concentration> 100 mg/L [16].
Within selected severity groups, we compared the distri-
bution of TLR9 -1237 and +2848 genotypes. For statistical
analysis, SPSS for Windows 17.0 and Graphpad Prism 5
were used. Genotype distributions were checked for devia-
tions of the Hardy-Weinberg equilibrium (HWE). Reces-
sive and dominant models were used to model the
relations between genotype distributions and clinical vari-
ables. Histograms were used to assess normality of the
clinical variables. T-tests, Mann–Whitney U tests, and χ2
test or Fisher’s exact tests were used where appropri-
ate. Outliers (< 4%) were excluded by the Grubbs’
test (p< 0.01) before continuous testing. P values< 0.05
were considered statistically significant.
Results
Table 1 shows the distribution and characteristics of the
severity variables in the study population. Differences in
numbers of patients are due to missing or non-
determined data in patient records.
Continuous variables i.e. duration of clinical illness,
rectal temperature, CSF leukocyte numbers, CSF/blood
glucose ratios, CSF protein concentrations, blood leuko-
cytes, and serum CRP concentrations were compared
between carriers of wild type (WT) alleles and mutant
alleles in MM patients for TLR9 -1237 and TLR9 +2848
respectively. Figure 1A shows that CSF leukocyte num-
bers were significantly higher in MM patients carrying
the TLR9 -1237 TC or CC genotypes compared to car-
riers of the TT WT genotype (median 2117, interquartile
range (IQR) 4987 versus median 955, IQR 3938).Table 2 TLR9 -1237 SNPs and severity variables in meningoco
Severity variable TLR9 -1237 N (%)
TT TC
N. meningitidis in blood culture
Positive 127 (80) 29 (18)*
Not detected 124 (68) 52 (29)*
Total 251 81
CSF leukocytes per μL
≤ 1000 129 (78) 34 (21)*
> 1000 127 (68) 52 (29)*
Total 253 87
CSF/blood glucose ratio
≤ 0.4 114 (69) 46 (28)*
> 0.4 90 (82) 18 (16)*
Total 204 64
* = significance p< 0.05.
Abbreviations: TLR: Toll-like receptor, OR: Odds ratio, 95% CI: 95% confidence interva
or non determined data in patient records.CSF/blood glucose ratios were significantly lower in
TLR9 -1237 TC or CC carriers than in carriers of the TT
WT (p= 0.017, median 0.20, IQR 0.4 versus median
0.35, IQR 0.5) (Figure 1B). CSF leukocytes/μL were sig-
nificantly higher in patients carrying the TLR9 +2848
AA mutant compared to children with genotype GG or
GA. (p= 0.0067, median 1907, IQR 5221 versus median
891, IQR 3952) (Figure 1C). There was no significant
difference in CSF/blood glucose ratios for TLR9 +2848
genotypes (results not shown).
No significant differences in genotype distributions
of −1237 and +2848 SNPs were found for the other
continuous variables (data not shown).
Dichotomous variables, i.e. blood culture, convulsions
in patient history, level of consciousness at admission,
ICU admission, sepsis and hearing loss and the dichoto-
mized continuous variables (as described above) were
compared between WT carriers and mutant carriers.
TLR9 -1237 TC or CC mutant carriers were compared
to the TT WT carriers. Significant associations are
shown in Table 2. The TLR9 -1237 TC and CC geno-
types were associated with a decreased incidence of a
positive blood culture for N. meningitidis (p= 0.014,
odds ratio (OR) 0.5, 95% confidence interval (CI) 0.3 – 0.9).
These genotypes were also associated with CSF leukocyte
levels> 1000 per μL (p=0.029, OR 1.7, 95% CI 1.1 – 2.8),
and with a CSF/blood glucose ratio≤0.4 (p=0.015, OR 2.0;
95% CI 1.1 – 3.6).
No significant differences in TLR9 -1237 genotype dis-
tribution were observed between the groups classified by
the other severity variables (data not shown).
TLR9 +2848 mutant carriers were compared with WT
carriers. Significant associations are shown in Table 3.ccal meningitis patients (p<0.05)
P OR 95% CI
CC Total
3 (2)* 159 0.014 0.5 0.3 – 0.9
6 (3)* 182
9 341
2 (1)* 165 0.029 1.7 1.1 – 2.8
6 (3)* 183
8 348
6 (4)* 166 0.015 2.0 1.1 – 3.6
2 (2)* 110
8 276
l, CSF: cerebrospinal fluid. Different numbers within groups are due to missing
Table 3 TLR9 +2848 SNPs and severity variables in meningococcal meningitis patients (p< 0.05)
Severity variable TLR9 +2848 N (%) P OR 95% CI
GG GA AA Total
N. meningitidis in blood culture
Positive 42 (27) 80 (51) 36 (23)* 158 0.017 0.6 0.3 – 0.9
Negative 40 (22) 79 (43) 63 (35)* 182
Total 82 159 99 340
CSF leukocytes/μL
≤ 600 36 (27) 66 (50) 30 (23)* 132 0.028 1.7 1.1 – 2.9
> 600 50 (24) 91 (43) 72 (34)* 213
Total 86 157 102 345
≤ 1000 41 (25) 85 (53) 36 (22)** 162 0.005 2.0 1.2 – 3.2
> 1000 45 (25) 72 (39) 66 (36)**
Total 86 157 102
* = significance p< 0.05, ** = significance p< 0.01
Abbreviations: TLR: Toll-like receptor, OR: Odds ratio, 95% CI: 95% confidence interval, CSF: cerebrospinal fluid. Different numbers within groups are due to missing
or non determined data in patient records.
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dence of a positive blood culture (p = 0.017, OR 0.6,
95% CI 0.3 – 0.9). The TLR9 +2848 AA mutant was
also significantly more present in children with> 600
and> 1000 leukocytes per μL (p = 0.028, OR 1.7, 95%
CI 1.1 – 2.9 and p = 0.005, OR 2.0, 95% CI 1.2 – 3.2
respectively).
No significant differences for TLR9 +2848 genotype
distribution were observed between the groups classified
by the other severity variables (data not shown).
Table 4 shows that TLR9 haplotype I was very sig-
nificantly associated with blood cultures positive for
N. meningitidis (p= 0.001, OR 1.5, 95% CI 1.1 – 2.0).Table 4 TLR9 haplotypes and severity variables in meningoco
Severity variable TLR9 haplotype¹N (%)
I II
TLR9-1237 T T
TLR9+ 2848 G A
N. meningitidis in blood culture
Positive 162 (51)** 119 (38)
Negative 148 (41)** 147 (41)
Total 310 266
CSF leukocytes per μL
≤ 1000 164 (50)* 122 (38)
>1000 154 (42)* 144 (40)
Total 31 266
¹ haplotypes as defined by Lazarus et al. [12].
* = significance p< 0.05. ** = significance p< 0.01.
Abbreviations: TLR: Toll-like receptor CSF: cerebrospinal fluid, OR: odds ratio.
Different numbers within groups are due to missing or non determined data in patHaplotype I was also significantly associated with
decreased CSF leukocytes (less than 1000/μL: p= 0.03;
OR 0.7 95% CI 0.5–1.0). No significant differences in
haplotype distribution were observed for other sever-
ity variables (data not shown).
Discussion
We demonstrate that the TLR9 -1237 and +2848 SNPs are
associated with severity variables in a cohort of MM survi-
vors. In order to assess the biological consequence of this
statistical association we focus on the essential steps in
BM pathogenesis and the recognition of N. meningitidis
by TLR9. Meningococci colonize the nasopharynx andccal meningitis patients (p<0.05)
P OR 95% CI
III IV Total
C C 2 N
A G
33 (10) 2 (1) 316 0.001 1.5 (1.1 2.0) –
59 (16) 4 (1) 358
92 6 674
36 (11) 2 (1) 324 0.03 0.7 (0.5 1.0) –
60 (17) 4 (1) 362
96 6 686
ient records.
Figure 2 Schematic diagram of Toll-like receptor-9 (TLR9) -1237 and +2848 SNP positions and transcription factor (TF) binding sites in
the TLR9 promotor region. In silico analyses show that the C allele at position −1237 creates extra putative binding sites for Nuclear Factor
kappa B (NFκB), avian reticuloendotheliosis viral oncogene homolog A (RelA) and signal transducer and activator of transcription (STAT3). RelA is
able to bind to NFkB to form the NFkB complex. STAT3 is able to activate transcription in the nucleus in response to cytokines. These processes may
upregulate the expression of TLR9, altering the TLR9 initiated innate immune response to meningococcal DNA, affecting the clinical severity of
meningococcal meningitis (partly adapted from Ng et al., [13]. Abbreviations: TF: transcription factor, R: A/G, N: any base, Y: C/T, W: A/T, D: A/T/G.
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tory tract by transcellular passage of epithelial cells [19].
During this process meningococci are recognized by intra-
cellular TLR9 of sinonasal epithelial cells [20]. After pas-
sage of this epithelial barrier meningococci are able to
pass directly from the nasopharynx to meninges through
the olfactory nerve system but more frequently they will
enter the bloodstream [21]. Survival of bacteria within
the circulation is a prerequisite for meningeal invasion.
Complement-mediated opsonophagocytosis of N. menin-
gitidis leads to activation of phagocytosing cells via TLR9
[22]. Upon survival in the bloodstream meningococci may
attach to and traverse the blood–brain barrier by endo-
cytosis, they will multiply in the subarachnoidal space and
are recognized by astrocytes and microglia, dendritic cells
and macrophages of the brain respectively and in direct
contact with the CSF [23]. After being phagocytosed,
meningococcal DNA motifs activate endosomal TLR9 and
subsequent signal transduction occurs, stimulating the
production of cytokines inside the CNS and chemokines
leading to leukocyte recruitment towards the CNS [24,25].
We associated TLR9 SNPs with protection against
meningococcemia, a prerequisite for meningeal invasion,
and with elevated CSF leukocyte levels during MM. A
decreased incidence of positive blood cultures in chil-
dren carrying TLR9 -1237 C allele and TLR9 +2848 AA
genotypes may represent a reduction in the occurrence
of secondary bacteremia due to more pronounced host
immune response in the CSF. A possible mechanistic ex-
planation and biological consequence is increased NFκB
binding to the TLR9 promotor region, leading to
increased transcriptional regulation of TLR9 [13]. Weconfirmed this mechanism in our study population using
a novel in silico regulatory SNP detection method as
described by McIntyre et al. [26]: The TLR9 -1237 “C”
variant was associated with significantly increased bind-
ing of NFκB, avian reticuloendotheliosis viral oncogene
homolog A (RelA) and signal transducer and activator
of transcription (STAT3) to the TLR9 -1237 C variant
(Figure 2). According to these predictions, the TLR9 -
1237 C allele creates an increased affinity for NFκB
which in its turn increases the transcriptional activity of
the gene, leading to enhanced production of cytokines
and chemokines. This effect was present in stimulated
cells, but not under basal conditions, which may explain
an association of TLR9-1237 with severity, but not sus-
ceptibility to MM. Carvalho et al. reported that the C al-
lele of TLR9-1237 introduced a new IL-6-dependent
transcription factor binding site in the TLR9 promoter.
Peripheral blood mononuclear cells (PBMCs) harbouring
the TC genotype show higher expression of both TLR9
and IL-6 and increased B-cell proliferation in response
to CpG [27]. Another study showed higher serum Inter-
feron gamma levels in children carrying the TLR9-1237-C
allele with cerebral malaria, indicating that enhanced
TLR9 mediated immune responses are also relevant inside
the CNS [28]. The +2848 SNP does neither result in an
amino acid change nor to the modification of a regulatory
site, implying linkage of a functional relevant SNP in the
vicinity of this SNP.
In a mouse meningococcal bacteremia model the role
of TLR9 in preventing bacteremia was also confirmed.
TLR9 KO mice displayed reduced survival and elevated
levels of bacteremia compared to WT mice [22]. We
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bacteremia and higher levels of leukocytes in the CSF.
The link between systemic inflammation and pleocytosis
was previously studied. Intravenous injection of LPS
prior to intracisternal LPS injection in rabbits led to
impaired pleocytosis, reduced levels of TNF-α, and
impaired leukocyte influx into the CNS reflecting an
impaired inflammatory response in the CNS [29].
Clinical studies show that the most severely affected
patients with MM or septic shock with a rapidly evolv-
ing septic shock associated with high mortality have sig-
nificant lower levels of pleocytosis [30]. Although we
found an association of TLR9 SNPs with bacteremia, no
association was found with clinical sepsis. We propose
that TLR9 -1237 and +2848 polymorphisms have a bene-
ficial effect on preventing bacteremia and increase the
leukocyte influx in the CNS, reflecting an enhanced im-
mune response inside the CNS.
Although CNS inflammation is necessary to guarantee
sterility of the CNS, its injurious properties are also evi-
dent. An adequate but balanced inflammatory response
inside the CNS is essential in limiting adverse outcome
of disease. We concluded that TLR9 polymorphisms
have a small but possibly important contribution to war-
rant balance between beneficiary and injurious effects of
inflammation in the CNS. For exact consequences of
these SNPs, future studies focussing on TLR9 SNPs and
long term consequences of BM should be performed.
This study does have certain aspects that limit the
interpretations. Survivors of MM were retrospectively
included in our study. DNA from children with fatal
meningitis were not a focus of our study because includ-
ing survivors of MM allows us to obtain detailed infor-
mation on follow-up and long term consequences of the
disease which are of particular clinical relevance. In
addition, the number of patients with fatal meningitis is
very low in The Netherlands. The effect of treatment of
BM was not incorporated in this study. This effect may
not be of great influence since comparable protocols for
treatment of BM were used nationwide in the period
these children have been admitted to Dutch hospitals,
and timing of treatment is divided equally between
groups and independent of genotype distribution.
Multidisciplinary efforts are needed in order to bundle
and translate genetic studies into beneficial interventions
(personalized medicine, risk profiling, disease treatments
with better specificity and innovative drug therapies)
enforced by the field called Public Health Genomics [31].
We have performed several statistical analyses and
therefore also performed corrections for multiple testing.
Using the rough false discovery rate (rFDR) would shift
the threshold for statistical significance from <0.05 to
<0.026, reducing the number of significant associations
described in this paper. Using the more conservativeHolm-Bonferroni corrections, shifts the threshold to
<0.002, resulting in one remaining significant associ-
ation (TLR9 haplotype I and N. meningitidis). Although
the multiple testing corrections reduce the number of
statistically significant associations of the exploratory
study, the trends that remain give indications for poten-
tial roles of the studied variables in the severity of bac-
terial meninigitis.
More association and functional studies on TLR9 SNPs,
functional consequences and long term effects in the CNS
are needed to reveal the exact mechanism causing the dif-
ferences in clinical course of MM and to obtain genetic
traits which can be used for patient profiling and manage-
ment of meningitis patients.
Conclusions
In this study, TLR9 -1237 and TLR9 +2824 mutant geno-
types were associated with protection against meningo-
coccemia, an essential prerequisite for meningeal invasion.
We also associated these SNPs with enhanced local in-
flammatory responses inside the CNS. Carriers of the
TLR9+2848 mutant genotype have a lower chance of
developing meningitis when colonized with N. meningitidis.
When they eventually do so, they will have more efficient
bacterial killing inside the CNS but may also result in a
higher chance of developing neurological sequelae.
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